• 7TM Pharma, of Horsholm, Denmark, received an undisclosed milestone payment in its research collaboration within therapeutic angiogenesis with Procter & Gamble Pharmaceuticals Inc., a subsidiary of Cincinnati-based Procter & Gamble Co. The milestone was triggered by successful progress in the preclinical development of drug candidates for treating diseases, such as peripheral arterial disease and coronary artery disease related to arteriosclerosis. 7TM entered the research agreement with P&G in January 2005.

• Adolor Corp., of Exton, Pa., completed its previously announced public offering of 5 million shares, plus 750,000 shares in overallotments, priced at $25 each. Net proceeds are about $135 million, and will be for general corporate purposes, such as increasing working capital, acquisitions and in-licensing activities, and capital expenditures. (See BioWorld Today, Feb. 17, 2006.)

• Biofusion plc, of Sheffield, UK, spun out a new company, Genophrenix Ltd., from its pipeline agreement with the University of Sheffield to capitalize on the discovery of specific proteins involved with a biochemical pathway implicated in neuropsychiatric diseases, including schizophrenia. Biofusion owns a 60 percent shareholding in the company.

• Cambrex Bio Science Walkersville Inc., of Walkersville, Md., a subsidiary of Cambrex Corp., said its client Chugai Pharmaceutical Co. Ltd., of Tokyo, completed an assessment of certain Clonetics Conditionally Immortalized Cell Lines and signed a one-year renewable license agreement to use a cell line in its drug discovery programs for metabolic diseases. The cell lines were created using a clone of a specially modified large T antigen and licensed telomerase technology.

• Chembio Diagnostics Inc., of Medford, N.J., appointed Seterna Ltd. to distribute its rapid HIV tests in Ethiopia, which has an estimated 1.5 million people infected with HIV. The rapid tests identify patients who may require antiretroviral treatment. Ethiopia currently is evaluating Chembio’s two HIV 1/2 STAT-PAK tests for possible inclusion in the country’s testing protocol.

• Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Rosetta Genomics Ltd., of Rehovot, Israel, formed a joint research collaboration to discover and develop antisense drugs that regulate microRNAs for the treatment of the most prevalent type of liver cancer, hepatocellular carcinoma. Isis’ published research demonstrates pharmacological activity in vivo using well validated antisense chemistry to inhibit miRNAs.

• Nanosyn Inc., of Menlo Park, Calif., and Amphora Discovery Corp., of Research Triangle Park, N.C., entered a multiyear research collaboration in which Nanosyn will provide chemistry-based services to Amphora for multiple drug targets. Under the terms, Amphora will own all compounds and their methods of use, and Nanosyn will receive an up-front fee, research funding and success-based milestones.

• Novelos Therapeutics Inc., of Newton, Mass., submitted a proposal for the use of NOV-002 to treat subjects exposed to lethal injection, in response to a recent request for proposals from the Department of Health and Human Services. In preclinical testing, treatment of animals with NOV-002 after radiation exposure resulted in a two- to threefold increase in 30-day survival compared to the irradiated animals that were not treated. The product is in Phase III development for lung cancer in combination with chemotherapy.

• Pharmacopeia Drug Discovery Inc., of Princeton, N.J., said it discovered a class of compounds that target a kinase involved in metabolic diseases through its collaboration with Stockholm, Sweden-based Biovitrum AB. Building on this achievement, the companies will take the compound series into the next stage, focusing on optimization and advancing a compound toward the clinic. Under the collaboration terms, Biovitrum would be responsible for advancing candidates through preclinical and clinical development and onto the market, and Pharmacopeia would be entitled to milestones and royalties.

• Qiagen NV, of Venlo, the Netherlands, and ActiveSight, of San Diego, entered a co-marketing agreement related to protein crystallography for drug discovery. The agreement seeks to ease access to protein crystallization reagents and crystallographic services. Financial terms were not disclosed.

• Valeant Pharmaceuticals Inc., of Costa Mesa, Calif., said the FDA has approved less-restrictive labeling for Tasmar (tolcapone), its COMT (catechol-O-methyltransferase) inhibitor product for Parkinson’s disease patients undergoing treatment with levodopa/carbidopa. The new labeling calls for less frequent laboratory monitoring for patients taking the drug, and allows patients to remain on Tasmar at higher ALT levels than previously required.

No Comments